Luis Garcia Barreto, MD
Pulmonary Disease · Coamo, PRNPI 1659450500
Payments from drug & device makers
Across 594 payments — averaging $661.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$199K
- Pfizer$94K
- Bayer$38K
- Pfizer Pharmaceuticals LLC$35K
- Merck$17K
- AstraZeneca$4K
- plus $6K from 20 others
What the payments were for
- Consulting fees$3,0511%
- Speaking & faculty fees$352,05890%
- Travel & lodging$20,2605%
- Food & beverage$17,1094%
- Education$1510%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 203 | $199,074 |
| Pfizer | 73 | $93,636 |
| Bayer | 36 | $38,255 |
| Pfizer Pharmaceuticals LLC | 45 | $34,850 |
| Merck | 38 | $16,860 |
| AstraZeneca | 108 | $3,602 |
| E.r. Squibb & Sons, L.L.C. | 2 | $1,561 |
| Boehringer Ingelheim | 36 | $1,324 |
| Jazz Pharmaceuticals Inc. | 10 | $729 |
| United Therapeutics Corporation | 9 | $707 |
| Viiv Healthcare Company | 1 | $600 |
| Sanofi | 9 | $501 |
| Actelion Pharmaceuticals US, Inc. | 2 | $216 |
| Genentech USA, Inc. | 4 | $124 |
| Dexcom, Inc. | 1 | $114 |
| Mallinckrodt Hospital Products Inc. | 1 | $99 |
| Mylan Specialty L.p. | 1 | $97 |
| Gilead | 5 | $95 |
| Veloxis Pharmaceuticals, Inc. | 1 | $54 |
| Johnson & Johnson | 2 | $39 |
| Medtronic | 1 | $33 |
| PBG Puerto Rico LLC | 2 | $23 |
| Mylan LLC | 1 | $20 |
| Insmed, Inc. | 1 | $14 |
| Bayer Puerto Rico Inc. | 1 | $13 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$87,983
- NUCALA$76,578
- ABRYSVO$43,843
- PREVNAR 20$42,790
- PREVNAR - 13$38,700
- Adempas$37,643
- ANORO ELLIPTA$19,986
- WINREVAIR$13,415
- AREXVY$10,047
- OPDIVO$1,526
- PNEUMOVAX 23$1,500
- KEYTRUDA$1,125
- TYVASO$367
- DUPIXENT$270
- TEZSPIRE$250
- XYWAV$250
- FASENRA$245
- ORENITRAM$243
- ELIQUIS$124
- UPTRAVI$118
How this compares
$392,646 in reported general payments places this provider in the 95th percentile of 138 pulmonary disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 105 | $1,459,250 |
| OpsumitMacitentan | 24 | $302,157 |
| OfevNintedanib Esylate | 21 | $276,258 |
| NucalaMepolizumab | 43 | $157,168 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 283 | $140,133 |
| Spiriva RespimatTiotropium Bromide | 224 | $124,839 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 161 | $106,888 |
| Pirfenidone | 53 | $102,358 |
| Breo ElliptaFluticasone/Vilanterol | 236 | $100,921 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 236 | $66,027 |
| Dupixent SyringeDupilumab | 14 | $52,497 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,074 | $43,950 |
| Theophylline ErTheophylline Anhydrous | 282 | $37,911 |
| Arnuity ElliptaFluticasone Furoate | 135 | $36,505 |
| Wixela InhubFluticasone Propion/Salmeterol | 198 | $32,045 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerAdempas | $38,255 | $1,459,250105 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $1,324 | $541,230528 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta | $199,074 | $416,723603 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $216 | $302,15724 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $3,602 | $44,166133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 138 pulmonary disease providers in Puerto Rico.
Other pulmonary disease in Coamo
- Alvaro Aranda RodriguezGuaynabo$1.9M
- Edgardo Cartagena AyalaSan Juan$1M
- Domingo Chardon FelicianoPonce$152K
- Luis Nieves GarrasteguiRio Piedras$121K
- Jahaira Serrano DominguezArecibo$102K
- Ramon FloresSan Juan$86K
- William Villanueva-BosqueArecibo$67K
- Joel Nieves ScharonSan Juan$55K
- George FahedPonce$16K
- William RodriguezSan Juan$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.